{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T16:47:51Z","timestamp":1777308471267,"version":"3.51.4"},"reference-count":43,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Pfizer Italy"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/13696998.2026.2658451","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T16:07:51Z","timestamp":1777306071000},"page":"1372-1386","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness analysis of lorlatinib as first-line treatment for anaplastic lymphoma kinase (ALK)-positive non\u2013small cell lung cancer in Italy"],"prefix":"10.1080","volume":"29","author":[{"given":"Ilaria","family":"Valentini","sequence":"first","affiliation":[{"name":"Universit\u00e0 Cattolica del Sacro Cuore","place":["Rome, Italy"]},{"name":"ALTEMS Advisory, Spin-off Universit\u00e0 Cattolica del Sacro Cuore","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filippo","family":"Rumi","sequence":"additional","affiliation":[{"name":"Universit\u00e0 Cattolica del Sacro Cuore","place":["Rome, Italy"]},{"name":"ALTEMS Advisory, Spin-off Universit\u00e0 Cattolica del Sacro Cuore","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugenio","family":"Di Brino","sequence":"additional","affiliation":[{"name":"Universit\u00e0 Cattolica del Sacro Cuore","place":["Rome, Italy"]},{"name":"ALTEMS Advisory, Spin-off Universit\u00e0 Cattolica del Sacro Cuore","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1020-2338","authenticated-orcid":false,"given":"Alessandra","family":"Bearz","sequence":"additional","affiliation":[{"name":"IRCCS Centro Di Riferimento Oncologico Aviano","place":["Aviano, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Pasello","sequence":"additional","affiliation":[{"name":"Department of Surgery, Oncology and Gastroenterology, University of Padova","place":["Padova, Italy"]},{"name":"IOV Istituto Oncologico Veneto IRCCS","place":["Padova, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Novelli","sequence":"additional","affiliation":[{"name":"Pfizer s.r.l","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Di Virgilio","sequence":"additional","affiliation":[{"name":"Pfizer s.r.l","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Basile","sequence":"additional","affiliation":[{"name":"Universit\u00e0 Cattolica del Sacro Cuore","place":["Rome, Italy"]},{"name":"ALTEMS Advisory, Spin-off Universit\u00e0 Cattolica del Sacro Cuore","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"key":"e_1_3_6_2_1","unstructured":"Ministero della Salute. I numeri del cancro in Italia 2024. [Internet]; 2024 [cited 2026 Jan 18]. https:\/\/www.salute.gov.it\/imgs\/C_17_pubblicazioni_3510_allegato.pdf"},{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2025.102905"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/0300891619857418"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-023-02990-y"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-22-883"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-1337"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0318"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2018.05.012"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000548"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy275"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2025.2612605"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.05.010"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1420785112"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00581"},{"key":"e_1_3_6_16_1","unstructured":"European Medicines Agency (EMA). Summary of opinion (initial authorisation) Lorviqua (lorlatinib); 2019 [cited 2026 Jan 19]. https:\/\/www.ema.europa.eu\/en\/documents\/smop-initial\/chmp-summary-positive-opinion-lorviqua_en.pdf."},{"key":"e_1_3_6_17_1","unstructured":"European Medicines Agency. SmPC. LORVIQUA (lorlatinib); 2022 [cited 2026 Jan 19]. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lorviqua-epar-product-information_en.pdf."},{"key":"e_1_3_6_18_1","unstructured":"AGENZIA ITALIANA DEL FARMACO. Determina_707-2023_Lorviqua. 2026 [cited 2026 Jan 19]. https:\/\/www.aifa.gov.it\/documents\/20142\/961234\/Determina_707-2023_Lorviqua.pdf."},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-021-02204-0"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2020.08.2094"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2027187"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03320659"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(22)00437-4"},{"key":"e_1_3_6_24_1","unstructured":"European Medicines Agency. Annex I summary of product characteristics: alecensa INN-alectinib. 2017 [cited 2026 Jan 26]. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/alecensa-epar-product-information_en.pdf."},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2024.08.003"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2024.10.3140"},{"key":"e_1_3_6_27_1","unstructured":"Istituto Italiano di Statistica (ISTAT). Tabelle di Mortalit\u00e0 italia; 2025. https:\/\/www.google.com\/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&cad=rja&uact=8&ved=2ahUKEwjDyr2144r7AhW3X_EDHUhnAfUQFnoECBQQAQ&url=http%3A\/\/dati.istat.it\/Index.aspx%3FDataSetCode%3DDCIS_MORTALITA1&usg=AOvVaw1Ul_RJJCCHwMtK8aOpuH1b"},{"key":"e_1_3_6_28_1","unstructured":"NICE. Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer technology appraisal guidance reference number: TA909 [Internet]. NICE; 2025 [cited 2026 Jan 26]. https:\/\/www.nice.org.uk\/guidance\/ta1103."},{"key":"e_1_3_6_29_1","unstructured":"NICE. Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor technology appraisal guidance reference number: TA670 [Internet]. NICE; 2021 [cited 2026 Jan 26]. https:\/\/www.nice.org.uk\/guidance\/ta670"},{"key":"e_1_3_6_30_1","unstructured":"National Institute for Health and Care Excellence. [TA536] Alectinib for untreated ALK-positive advanced non-small-cell lung cancer; 2018. https:\/\/www.nice.org.uk\/guidance\/ta536"},{"key":"e_1_3_6_31_1","unstructured":"Agenzia Italiana del Farmaco (AIFA). Elenco dei farmaci di fascia A e H per principio attivo. 2024. https:\/\/www.aifa.gov.it\/liste-farmaci-a-h."},{"key":"e_1_3_6_32_1","unstructured":"Ministero della Salute. Tariffario delle prestazioni di assistenza ambulatoriale; 2017. https:\/\/www.trovanorme.salute.gov.it\/norme\/renderPdf.spring?seriegu=SG&datagu=18\/03\/2017&redaz=17A02015&artp=4&art=1&subart=1&subart1=10&vers=1&prog=001."},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2024.10.524"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-020-01190-z"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-021-01015-8"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S415711"},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2023.2288249"},{"key":"e_1_3_6_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-023-01279-2"},{"key":"e_1_3_6_39_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.684073"},{"key":"e_1_3_6_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2025.03.014"},{"key":"e_1_3_6_41_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.985834"},{"key":"e_1_3_6_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.12477"},{"key":"e_1_3_6_43_1","unstructured":"Osservatorio JobPricing. Salary Outlook \u2013 2026. 2026. https:\/\/osservatoriojobpricing.it\/report\/salary-outlook"},{"key":"e_1_3_6_44_1","doi-asserted-by":"crossref","first-page":"101819","DOI":"10.1016\/j.jth.2024.101819","article-title":"Impact of distance and\/or travel time on healthcare service access in rural and remote areas: a scoping review","volume":"37","author":"Mseke EP","year":"2024","unstructured":"Mseke EP, Jessup B, Barnett T. Impact of distance and\/or travel time on healthcare service access in rural and remote areas: a scoping review. J Transp Health. 2024;37:101819.","journal-title":"J Transp Health"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2026.2658451","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T16:07:59Z","timestamp":1777306079000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2026.2658451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/13696998.2026.2658451"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2026.2658451","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-03-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-02","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}